Apyx Medical Corporation (NASDAQ:APYX) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analyst consensus: Six analysts give Apyx Medical a consensus "Moderate Buy" (1 sell, 1 hold, 3 buy, 1 strong buy) with an average 12‑month target of $6.50.
• Recent results: Apyx slightly beat estimates for the quarter (EPS -$0.03 vs -$0.06; revenue $19.16M vs $19.12M) but remains unprofitable (negative ROE 114.95% and net margin -21.22%), with analysts projecting FY EPS of -0.34.
• Market metrics and ownership: Shares trade around $3.46 (1‑year range $0.90–$4.50) with a market cap of about $145M, a debt‑to‑equity of 2.35, and roughly 55% institutional ownership while several hedge funds recently adjusted positions.

Shares of Apyx Medical Corporation (NASDAQ:APYX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $6.50.

Several research firms have recently weighed in on APYX. Wall Street Zen downgraded Apyx Medical from a "buy" rating to a "hold" rating in a research report on Sunday. Weiss Ratings reissued a "sell (d-)" rating on shares of Apyx Medical in a research report on Friday, March 27th. BTIG Research raised Apyx Medical from a "neutral" rating to a "buy" rating and set a $6.00 target price on the stock in a research report on Wednesday, March 11th. Finally, Craig Hallum upped their price objective on Apyx Medical from $5.00 to $6.00 and gave the company a "buy" rating in a research report on Wednesday, March 11th.

Apyx Medical Stock Performance

NASDAQ:APYX opened at $3.46 on Thursday. The company has a debt-to-equity ratio of 2.35, a current ratio of 5.00 and a quick ratio of 4.26. Apyx Medical has a 1 year low of $0.90 and a 1 year high of $4.50. The stock's 50 day simple moving average is $3.67 and its two-hundred day simple moving average is $3.70. The company has a market cap of $144.73 million, a price-to-earnings ratio of -12.81 and a beta of 1.54.

Apyx Medical (NASDAQ:APYX - Get Free Report) last released its earnings results on Tuesday, March 10th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.03. The firm had revenue of $19.16 million for the quarter, compared to the consensus estimate of $19.12 million. Apyx Medical had a negative return on equity of 114.95% and a negative net margin of 21.22%. As a group, equities analysts anticipate that Apyx Medical will post -0.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Apyx Medical

Hedge funds have recently bought and sold shares of the business. Huntleigh Advisors Inc. bought a new position in Apyx Medical in the 4th quarter valued at $827,000. Silverberg Bernstein Capital Management LLC grew its position in Apyx Medical by 4.7% in the 4th quarter. Silverberg Bernstein Capital Management LLC now owns 1,033,003 shares of the company's stock valued at $3,616,000 after acquiring an additional 46,500 shares during the last quarter. Royce & Associates LP grew its position in Apyx Medical by 1.4% in the 3rd quarter. Royce & Associates LP now owns 2,474,399 shares of the company's stock valued at $5,295,000 after acquiring an additional 34,696 shares during the last quarter. RPg Family Wealth Advisory LLC bought a new position in Apyx Medical in the 3rd quarter valued at $163,000. Finally, Caprock Group LLC bought a new position in Apyx Medical in the 3rd quarter valued at $40,000. Institutional investors own 55.33% of the company's stock.

Apyx Medical Company Profile

Apyx Medical NASDAQ: APYX is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company's product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.